MADISON, WI -- 08/05/09 --
TomoTherapy Incorporated (NASDAQ: TOMO) announced today that the 2009 meeting of the American Association of Physicists in Medicine
(AAPM) featured a comprehensive look at the current and future role of
TomoTherapy® technology in addressing complex cancer treatment
challenges. TomoTherapy users from around the world attended the AAPM
annual meeting, presenting on topics that addressed: the successful use of
TomoTherapy's unique radiation therapy solution across a wide range of
cases; planning studies documenting the clinical advantages of TomoTherapy
over treatments from conventional radiation therapy devices; and
investigations into radiobiological treatment improvements using the unique
CT scanner-based TomoTherapy platform.
AAPM is the largest association of medical physicists in the world. The
2009 annual meeting was held in Anaheim, Calif., from July 26 to July 30.
Below is a sampling of more than 50 TomoTherapy-related topics from the
conference. For a comprehensive look at AAPM 2009 abstracts, visit
TomoTherapy.com.
-- Biological Effect of Different IMRT Delivery Techniques: SMLC, DMLC and
Helical TomoTherapy
Karmanos Cancer Center, Detroit,
Mich., presented an analysis of various IMRT delivery techniques, including
SMLC (step-and-shoot), DMLC (sliding window) and helical TomoTherapy. The
purpose was to investigate the impact on cell survival of various temporal
dose characteristics. The study finds helical TomoTherapy to be
"biologically superior" to conventional techniques, based on reduced dose
accumulation times for individual target elements (e.g. tumor cells).
-- Dosimetric Characterization of Whole Brain Radiotherapy (WBRT) using
Helical TomoTherapy
The Cancer
Treatment and Research Center (CTRC), San Antonio, Tex., compared the
dosimetric quality of TomoTherapy to conventional WBRT techniques. Results
indicate that significant sparing of radiation exposure to the left and
right eyes can be achieved when using TomoTherapy.
-- Multicenter Intercomparison for Treatment of Mesothelioma with IMRT and
TomoTherapy
Azienda
Ospedaliero - Universitaria di Modena, Modena, Italy, evaluated
TomoTherapy IMRT (intensity-modulated radiation therapy) against
conventional linear accelerator-based techniques for the treatment of
mesothelioma. The study reports that TomoTherapy is observed to allow
better coverage and uniformity of dose to the target volume with better
sparing of the nearby kidney and liver, in a faster treatment time.
-- Treatment Planning Study of Epithelial Ovarian Cancers Using Helical
TomoTherapy
Tata Memorial Centre, Advanced
Centre for Treatment, Research & Education in Cancer (ACTREC), Mumbai,
India, assessed the use of TomoTherapy for Whole Abdomen Radiotherapy (WAR)
of epithelial ovarian cancer. Their study states that TomoTherapy achieves
excellent coverage of the WAR target with simultaneous pelvic boost and
organ-at-risk sparing. The technique is being further evaluated in a phase
II cohort study.
Said Fred Robertson, CEO of TomoTherapy: "AAPM is always an important
meeting for TomoTherapy. This year's conference showcased a strong body of
work by our customers and research partners. We are pleased to see how our
platform is being harnessed to advance cancer care."
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the
TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy
system for the treatment of a wide variety of cancers. The Hi·Art treatment
system combines integrated CT imaging with conformal radiation therapy to
deliver sophisticated radiation treatments with speed and precision while
reducing radiation exposure to surrounding healthy tissue. The company's
stock is traded on the NASDAQ Global Select Market under the symbol TOMO.
To learn more about TomoTherapy, please visit TomoTherapy.com.
©2009 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the
TomoTherapy logo and Hi·Art are among trademarks, service marks or
registered trademarks of TomoTherapy Incorporated in the United States and
other countries.
Investor Contact:
Thomas E. Powell
Chief Financial Officer
608.824.2800
Email Contact
Media Contact:
Kevin O'Malley
Manager, Corporate Communications
608.824.3384
Email Contact
